Dexmedetomidine vs Lignocaine for Reducing Intubation-Induced Hemodynamic Responses in Cardiac Surgery: A Randomized Controlled Trial

Comparison of Intravenous Dexmedetomidine and Lignocaine in Reducing Hemodynamic Responses During Laryngoscopy and Endotracheal Intubation In Patients Undergoing Cardiac Surgery at Rawalpindi Institute Of Cardiology- A Randomized Controlled Trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07611890

Enrollment

Registered

2026-05-28

Start date

2026-05-21

Completion date

2026-08-21

Last updated

2026-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dexmedetomidine, Laryngoscopic Stress Response, Lignocaine

Keywords

Laryngoscopic stress response, Dexmedetomidine, Lignocaine, Cardiac surgery

Brief summary

After confirming eligibility, written informed consent will be obtained by a trained team member who is not involved in assigning treatment or giving the study medication. Each participant will receive a unique study number to protect privacy. Participants will be randomly assigned to receive one of the study medications using a chance-based method.The study medication will be administered through a vein before placement of the breathing tube. Blood pressure and pulse rate will be measured before the procedure and at several time points after the breathing tube is inserted.

Detailed description

After confirming eligibility, written informed consent will be obtained and each participant will be assigned a unique study ID to maintain confidentiality. Participants will be randomly allocated using a computer-generated random sequence implemented through the lottery method, with assignments placed in sealed opaque envelopes opened on the day of surgery. The study medication will be administered intravenously according to the study protocol before laryngoscopy and endotracheal intubation. Mean arterial pressure and heart rate will be recorded at baseline and at 1, 3, 5, and 10 minutes after intubation. Demographic information and study-related observations will be documented in a structured data collection form.

Interventions

DRUGIV dexmedetomidine

0.5 Mcg/kg of Dexmedetomidine will be given 10 minutes before laryngoscopy

DRUGIV Lignocaine

Patients will be given 1.5 mg/kg of Lignocaine 3 minutes before laryngoscopy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

American Society of Anesthesiologists (ASA) physical status III-IV. Patients who are at risk of cardiovascular events

Exclusion criteria

1. Patients with known hypersensitivity to dexmedetomidine and Lignocaine. 2. Patients on medications that could interfere with the study (e.g., beta-blockers, calcium channel blockers). 3. Pregnant or lactating women. 4. Patients with a history of airway anomalies or difficult intubation.

Design outcomes

Primary

Measure	Time frame
Mean Arterial Pressure	It will be expressed in millimeters of mercury (mmHg) and measured using an arterial catheter immediately before intubation and then at 1,3,5 and 10 minutes after intubation.
Heart Rate	It will be expressed as number of heart beats per minute and measured using pulse oximeter immediately before intubation and then at 1,3,5 and 10 minutes after intubation.

Countries

Pakistan

Contacts

CONTACTNamrah Zujaj, MBBS

zujajnamrah20@gmail.com+92 305 2636980

STUDY_CHAIRQudsia Anjum, MBBS,FCPS

Rawalpindi Institute of Cardiology

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 29, 2026